Marinus Pharmaceuticals 将来の成長

Future 基準チェック /56

Marinus Pharmaceuticalsは、67.6%と34.9%でそれぞれ年率67.6%で利益と収益が成長すると予測される一方、EPSはgrowで72.2%年率。

主要情報

67.6%

収益成長率

72.2%

EPS成長率

Pharmaceuticals 収益成長	19.3%
収益成長率	34.9%
将来の株主資本利益率	n/a
アナリストカバレッジ	Good
最終更新日	14 Nov 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

LSE:0JYL - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	71	-23	89	N/A	7
12/31/2025	51	-55	-40	N/A	10
12/31/2024	35	-116	-101	N/A	9
9/30/2024	31	-140	N/A	N/A	N/A
6/30/2024	30	-149	-121	-120	N/A
3/31/2024	28	-145	-114	-114	N/A
12/31/2023	31	-141	-118	-118	N/A
9/30/2023	31	-134	-113	-113	N/A
6/30/2023	26	-29	-119	-117	N/A
3/31/2023	22	-35	-128	-127	N/A
12/31/2022	25	-20	-115	-113	N/A
9/30/2022	20	-14	-115	-113	N/A
6/30/2022	28	-105	-80	-78	N/A
3/31/2022	28	-91	-69	-67	N/A
12/31/2021	15	-99	-58	-55	N/A
9/30/2021	15	-88	-52	-50	N/A
6/30/2021	5	-84	-71	-70	N/A
3/31/2021	4	-76	-63	-63	N/A
12/31/2020	2	-76	-61	-61	N/A
9/30/2020	0	-74	-61	-61	N/A
6/30/2020	N/A	-72	-58	-58	N/A
3/31/2020	N/A	-69	-51	-51	N/A
12/31/2019	N/A	-54	-49	-49	N/A
9/30/2019	N/A	-49	-42	-42	N/A
6/30/2019	N/A	-46	-37	-36	N/A
3/31/2019	N/A	-43	-34	-33	N/A
12/31/2018	N/A	-37	-28	-28	N/A
9/30/2018	N/A	-31	-23	-23	N/A
6/30/2018	N/A	-24	N/A	-19	N/A
3/31/2018	N/A	-19	N/A	-18	N/A
12/31/2017	N/A	-19	N/A	-19	N/A
9/30/2017	N/A	-20	N/A	-20	N/A
6/30/2017	N/A	-22	N/A	-24	N/A
3/31/2017	N/A	-27	N/A	-26	N/A
12/31/2016	N/A	-29	N/A	-25	N/A
9/30/2016	N/A	-30	N/A	-24	N/A
6/30/2016	N/A	-29	N/A	-23	N/A
3/31/2016	N/A	-25	N/A	-22	N/A
12/31/2015	N/A	-25	N/A	-20	N/A
9/30/2015	N/A	-21	N/A	-17	N/A
6/30/2015	N/A	-18	N/A	-14	N/A
3/31/2015	N/A	-17	N/A	-11	N/A
12/31/2014	N/A	-13	N/A	-9	N/A
9/30/2014	N/A	-12	N/A	-10	N/A
6/30/2014	N/A	-12	N/A	-8	N/A
3/31/2014	N/A	-11	N/A	-7	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 0JYLは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.1% ) よりも高い成長率であると考えられます。

収益対市場: 0JYL今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: 0JYL今後 3 年以内に収益を上げることが予想されます。

収益対市場: 0JYLの収益 ( 34.9% ) UK市場 ( 3.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: 0JYLの収益 ( 34.9% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 0JYLの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Marinus Pharmaceuticals 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Forecast to breakeven in 2026

Marinus Pharmaceuticals, Inc. Reaffirms Revenue Guidance for the Year 2024

Marinus Pharmaceuticals, Inc. Increases Earnings Guidance for Full Year 2024

Marinus Pharmaceuticals, Inc. Provides Earnings Guidance for 2024

Marinus Pharmaceuticals, Inc. Updates Revenue Guidance for the Fiscal Year 2023

Marinus Pharmaceuticals, Inc. Updates Revenue Guidance for the Fiscal Year 2023

Recent updates

Third quarter 2024 earnings released: US$0.42 loss per share (vs US$0.61 loss in 3Q 2023)

New minor risk - Profitability

Marinus Pharmaceuticals Announces Topline Results from Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives

New major risk - Financial position

Forecast to breakeven in 2026

New major risk - Financial position

Second quarter 2024 earnings released: US$0.63 loss per share (vs US$0.61 loss in 2Q 2023)

Marinus Pharmaceuticals, Inc. Reaffirms Revenue Guidance for the Year 2024

Marinus Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Marinus Pharmaceuticals Announces Ganaxolone Approves in China as First Treatment for Seizures Associated with CDKL5 Deficiency Disorder

Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from Russell Small Cap Completeness Index

Marinus Pharmaceuticals Announces Topline Results from Phase 3 Rise Trial of IV Ganaxolone in Refractory Status Epilepticus

Robbins LLP Files A Class Action Against Marinus Pharmaceuticals, Inc

Robbins LLP Files A Class Action Against Marinus Pharmaceuticals, Inc

Marinus Pharmaceuticals, Inc. Announces Key Business Updates for Tuberous Sclerosis Complex Program

New minor risk - Profitability

Marinus Pharmaceuticals, Inc. Increases Earnings Guidance for Full Year 2024

First quarter 2024 earnings released: US$0.68 loss per share (vs US$0.67 loss in 1Q 2023)

Marinus Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

New major risk - Share price stability

Marinus Pharmaceuticals, Inc. Provides Update on the Phase 3 RAISE Trial

Marinus Pharmaceuticals, Inc., Annual General Meeting, May 22, 2024

Full year 2023 earnings released: US$2.63 loss per share (vs US$0.51 loss in FY 2022)

Marinus Pharmaceuticals, Inc. Provides Earnings Guidance for 2024

Marinus Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 05, 2024

Marinus Pharmaceuticals, Inc. Announces Seven Presentations at AES 2023, New Publication in Epilepsia and Results from the Second Generation Formulation MAD Study

Marinus Pharmaceuticals, Inc. Updates Revenue Guidance for the Fiscal Year 2023

Marinus Pharmaceuticals, Inc. Updates Revenue Guidance for the Fiscal Year 2023

Marinus Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Second quarter 2023 earnings released: US$0.61 loss per share (vs US$1.06 loss in 2Q 2022)

Marinus Pharmaceuticals, Inc. Announces European Commission Approval of ZTALMY (Ganaxolone) Oral Suspension for Adjunctive Treatment of Epileptic Seizures Associated with CDKL5 Deficiency Disorder in Patients Two to 17 Years of Age

Marinus Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Marinus Pharmaceuticals, Inc. Receives Positive CHMP Opinion for ZTALMY®? (ganaxolone) for the Adjunctive Treatment of Seizures Associated with CDKL5 Deficiency Disorder

Marinus Pharmaceuticals, Inc. Appoints Sarah Noonberg as Member of the Board

First quarter 2023 earnings released: US$0.67 loss per share (vs US$0.53 loss in 1Q 2022)

Full year 2022 earnings released: US$0.51 loss per share (vs US$2.69 loss in FY 2021)

Marinus Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 07, 2023

Marinus Pharmaceuticals, Inc. Appoints Steve Pfanstiel as Chief Operating Officer

Marinus Pharmaceuticals, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Marinus Pharmaceuticals, Inc. Announces Board Changes

Marinus Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $59.9979 million.

Third quarter 2022 earnings released: EPS: US$1.93 (vs US$0.53 loss in 3Q 2021)

Marinus Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $59.9979 million.

Marinus Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Second quarter 2022 earnings released: US$1.06 loss per share (vs US$0.65 loss in 2Q 2021)

Marinus Pharmaceuticals, Inc. Provides Revenue Guidance for the Fiscal Year 2022

Marinus Pharmaceuticals Announces U.S. Commercial Launch of ZTALMY (Ganaxolone) for Seizures Associated with CDKL5 Deficiency Disorder

Marinus Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from Russell 2000 Dynamic Index

Marinus Pharmaceuticals Expands Enrollment Criteria to Support Recruitment in Phase 3 RAISE Trial in Refractory Status Epilepticus

First quarter 2022 earnings released: US$0.53 loss per share (vs US$0.74 loss in 1Q 2021)

Marinus Pharmaceuticals, Inc. Announces Resumption of Phase 3 RAISE Trial in Status Epilepticus

Marinus Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 12, 2022

Marinus Pharmaceuticals, Inc. Announces Publication in the Lancet Neurology of Ztalmy® (Ganaxolone) Phase 3 Marigold Trial Results

Marinus Pharmaceuticals, Inc. announced that it has received $1.230085 million in funding

Marinus Pharmaceuticals, Inc. announced that it has received $30 million in funding from Oaktree Capital Management, L.P.

Marinus Pharmaceuticals, Inc. Announces Delay to RAISE Phase 3 Clinical Trial in Status Epilepticus and Associated IV Ganaxolone Clinical Trials

Marinus Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 21, 2022

Marinus Pharmaceuticals, Inc. Announces New Clinical and Research Data to Be Presented At American Epilepsy Society Meeting

High number of new directors

Marinus Pharmaceuticals, Inc. Announces FDA Acceptance for Filing and Priority Review of New Drug Application for Ganaxolone in CDKL5 Deficiency Disorder

European Medicines Agency Grants Marinus Pharmaceuticals Accelerated Assessment of Ganaxolone for Treatment of CDKL5 Deficiency Disorder

Marinus Pharmaceuticals, Inc. Announces Topline Data from Open-Label Phase 2 Trial Evaluating Safety and Efficacy of Adjunctive Oral Ganaxolone Treatment in 23 Patients with Seizures Associated with Tuberous Sclerosis Complex

Marinus Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for Ganaxolone for the Treatment of Seizures Associated with CDKL5 Deficiency Disorder and Provides Pipeline Update

High number of new directors

Forecast to breakeven in 2024

Marinus Pharmaceuticals Provides an Update on its Clinical and Regulatory Development Activities

Revenue beats expectations

Marinus Pharmaceuticals, Inc. Announces Executive Changes, Effective April 12, 2021